ACLY overexpression is commonly observed in a variety of human malignancies, and its targeting reduces cancer cell proliferation both in vitro and in vivo 155; based on this evidence, ACLY inhibitors, originally designed for metabolic disorders, are now being tested as potential anti-cancer drugs 156. The gene discussed is ACLY; the disease is metabolic disease.